Teresa Carvalho, MS, science writer —

Larimar Therapeutics has received a patent relative to CTI-1601, its experimental and potentially disease-modifying treatment for Friedreich’s ataxia (FA), the company announced. The patent, No. 11,459,363 and titled “Materials and Methods for Treating Friedreich’s Ataxia,” provides protection for composition of matter relative to CTI-1601 until at least July 2040.

Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…